UCB's meeting with U.S. FDA defines path forward for Cimzia in rheumatoid arthritis

UCB announced today that it met the U.S. FDA and clarified the requirements for the approval of the Biologics License Application (BLA) for Cimzia, the first PEGylated anti-TNF, for the treatment of rheumatoid arthritis (RA).

The details can be read here.